User:Mr. Ibrahem/Serdexmethylphenidate/dexmethylphenidate
 | |
 | |
| Combination of | |
|---|---|
| Serdexmethylphenidate | Prodrug of dexmethylphenidate |
| Dexmethylphenidate | Catecholamine reuptake inhibitor |
| Clinical data | |
| Trade names | Azstarys |
| Other names | KP415 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Dependence liability | High[1] |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a combination medication used to treat attention deficit hyperactivity disorder (ADHD).[1] It is used in people at least six years old.[1] It is taken by mouth.[1]
Common side effects include decreased appetite, trouble sleeping, nausea, abdominal pain, anxiety, irritability, fast heart rate, and increased blood pressure.[1] Other side effects may include psychosis, priapism, Raynaud, and heart problems.[1] It has a high risk of abuse.[1] Safety in pregnancy is unclear.[1] It contains serdexmethylphenidate and dexmethylphenidate, which act as central nervous system stimulants.[1]
The combination was approved for medical use in the United States in 2021.[1] It is not approved in Europe or the United Kingdom as of 2022.[2] In the United States it costs about 400 USD per month as of 2022.[3] In the United States it is a Schedule II controlled substance.[1]
References[edit]
- ^ a b c d e f g h i j k l m n o "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. Archived from the original on 13 July 2021. Retrieved 13 July 2021.
- ^ "Serdexmethylphenidate + dexmethylphenidate". SPS - Specialist Pharmacy Service. 30 November 2018. Retrieved 31 October 2022.
{{cite web}}: CS1 maint: url-status (link) - ^ "Azstarys". Archived from the original on 31 October 2022. Retrieved 31 October 2022.